FibroBiologics is now evaluating its fibroblast platform in Hantavirus disease models, with particular emphasis on inflammatory cytokine modulation and endothelial permeability reduction. The company ...
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...
Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 FibroBiologics, Inc. (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product ...
HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results